valneva se glp-1 receptor agonist weight management diabetes treatments Frontiers GLP-1 Receptor Agonists as Treatments
Description
not using GLP-1 receptor agonists had significantly lower relative risks for mortality and respiratory failure, according to a presentation at the CHEST Annual Meeting.In a retrospective study, Saud Alawad, MBBS, third-year internal medicine resident at West Virginia University, and colleagues analyzed adults with a group 1 PAH
Read more about the new GLP-1 pill that outperformed oral semaglutide in a recent Phase III trial.
Get the details at ADW Diabetes.
Moreover, the addition of finerenone to this combination therapy could potentially provide stronger cardiorenal protective benefits
The Phase III trial of this pipeline drug for treating type 2 diabetes mellitus, non-alcoholic fatty liver disease, and obesity started on August 28, 2023
GLP-1 patches contain no GLP-1 drugs
